Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zolpidem. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 4/20 | 0.85 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.85 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.85 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.85 |
| ▸ | ALB | P02768 | 2/20 | 0.85 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.85 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.85 |
| ▸ | HPGD | P15428 | 1/20 | 0.85 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.85 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.85 |
| ▸ | TSPO | P30536 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zolpidem SCHEMBL17004049 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL8207467 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL1402195 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL29382172 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL30604720 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL7127421 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL17477 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL7575406 | 0.99 | GABRB2 (0.83) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL876109 | 0.99 | GABRB2 (0.83) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL22685033 | 0.99 | GABRB2 (0.83) | GABRB2GABRA1ALBOPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2668 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118750459-B | Zolpidem tartrate tablet and preparation method thereof | 常州市武进中医医院 | 2025-04-01 | — | — | CN | claimed |
| CN-117357493-B | Zolpidem tartrate orally disintegrating sustained-release tablet and preparation method thereof | 鲁南贝特制药有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118787750-B | Preparation method of pharmaceutical composition, product and application thereof | 文韬创新药物研究(北京)股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118787750-A | Preparation method of pharmaceutical composition, product and application thereof | 文韬创新药物研究(北京)股份有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-118750459-A | Zolpidem tartrate tablet and preparation method thereof | 常州市武进中医医院 | 2024-10-11 | — | — | CN | claimed |
| CN-118526460-A | Zolpidem tartrate tablet and preparation method thereof | 江苏豪森药业集团有限公司 | 2024-08-23 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-3324971-B1 | ZOLPIDEM COMPOSITION AND PROCESS FOR PREPARING THE SAME | ATHENA PHARMACEUTIQUES SAS (FR) | 2024-06-12 | — | — | EP | claimed |
| CN-117907368-A | Quantitative determination method for crystal form A, E in zolpidem tartrate medicinal crystal form D | 鲁南贝特制药有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117462481-A | Promoter for promoting nasal delivery of pharmaceutical ingredients and application thereof | 南京星叶生物科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-20020142050-A1 | Porous drug matrices and methods of manufacture thereof | ACUSPHERE INC. | 2002-10-03 | — | — | US | claimed |
| EP-1180020-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | Acusphere, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1163241-A1 | ZOLPIDEM SALTS | Synthon B.V. (NL) | 2001-12-19 | — | — | EP | claimed |
| WO-2001078725-A2 | MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC AGENT | SYNTHON B.V. (NL) | 2001-10-25 | — | — | WO | claimed |
| US-6242460-B1 | DOES NOT EXHIBIT A MELTING ENDOTHERM THAT CORRESPONDS TO ZOLPIDEM FREE BASE. | SYNTHON BV (NL) | 2001-06-05 | — | — | US | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000058310-A1 | ZOLPIDEM SALTS | SYNTHON B.V. (NL) | 2000-10-05 | — | — | WO | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |